Comparison · NCT04732949-626ba69c
SNG001 vs Placebo: Number of Patients Who Progressed to Severe Disease or Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SNG001 vs Placebo: Number of Patients Who Progressed to Severe Disease or Death. Trial comparisons, record NCT04732949-626ba69c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04732949-626ba69c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.107 | 0.0773 | 0.147 | wilson | |
| Risk in group 2 | 0.144 | 0.11 | 0.188 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0371 | -0.0897 | 0.0155 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.743 | 0.488 | 1.13 | log | |
| Odds ratio, group 1 over group 2 | 0.712 | 0.441 | 1.15 | log | |
| Number needed to treat, for one fewer participant with the outcome on SNG001 than on Placebo | 27 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SNG001 | Patients received SNG001 via inhalation using nebuliser, once a day for 14 days | 33 | 308 | OG000 |
| Group 2 | Placebo | Patients received Placebo via inhalation using nebuliser, once a day for 14 days | 45 | 312 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Who Progressed to Severe Disease or Death
- Description
The efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to severe disease or death was evaluated. Severe disease was defined by the Ordinal Scale for Clinical Improvement (OSCI) as a score between 5 and 7. Death was defined by an OSCI score of 8.
- Time frame
- Until Day 35
- Population
- The ITT analysis population consisted of all randomised patients. Here, the number of participants analyzed signifies the participants with available data that were analyzed for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
- NCT number
- NCT04732949
- Phases
- PHASE3
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Interventions
- SNG001, Placebo
- Lead sponsor
- Synairgen Research Ltd.
- Results first posted
- 2023-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04732949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04732949-626ba69c